



# HOT TOPICS IN CARDIOLOGIA 2024

**27 e 28 Novembre 2024**

Villa Doria D'Angri - Via F. Petrarca 80,  
Napoli

Rivascolarizzazione  
percutanea nella sindrome  
coronaria cronica: quali  
indicazioni dalle  
nuove linee guida?

Dr Marco Boccalatte  
Ospedale Santa Maria delle Grazie  
UOC Cardiologia con UTIC

# 2024 ESC Guidelines for the management of chronic coronary syndromes



## Authors/Task Force Members:

**Christiaan Vrints (ESC Chairperson) (Belgium), Felicita Andreotti (ESC Chairperson) (Italy), Konstantinos C. Koskinas (Task Force Co-ordinator) (Switzerland), Xavier Rossello (Task Force Co-ordinator) (Spain), Marianna Adamo (Italy), James Ainslie (United Kingdom), Adrian Paul Banning (United Kingdom), Andrzej Budaj (Poland), Ronny R. Buechel (Switzerland), Giovanni Alfonso Chiariello (Italy), Alaide Chieffo (Italy), Ruxandra Maria Christodorescu (Romania), Christi Deaton (United Kingdom), Torsten Doenst<sup>1</sup> (Germany), Hywel W. Jones (United Kingdom), Vijay Kunadian (United Kingdom), Julinda Mehilli (Germany), Milan Milojevic<sup>1</sup> (Serbia), Jan J. Piek (Netherlands), Francesca Pugliese (United Kingdom), Andrea Rubboli (Italy), Anne Grete Semb (Norway), Roxy Senior (United Kingdom), Jurrien M. ten Berg (Netherlands), Eric Van Belle (France), Emeline M. Van Craenenbroeck (Belgium), Rafael Vidal-Perez (Spain), Simon Winther (Denmark)**

<sup>1</sup> Representing the European Association for Cardio-Thoracic Surgery (EACTS)

## New recommendations (16)



### Recommendations

#### *Assessment of procedural risks and post-procedural outcomes*

Intracoronary imaging guidance by IVUS or OCT is recommended when performing PCI on anatomically complex lesions, in particular left main stem, true bifurcations, and long lesions.

Class

Level

I

A

#### Intracoronary pressure measurement (FFR or iFR) or computation (QFR):

- is recommended to guide lesion selection for intervention in patients with multivessel disease;
- should be considered at the end of the procedure to identify patients at high risk of persistent angina and subsequent clinical events;
- may be considered at the end of the procedure to identify amenable to treatment with additional PCI.

I

A

IIa

B

#### *Choice of revascularization modality*

It is recommended that physicians select the most appropriate revascularization strategy based on patient profile, coronary anatomy, procedural feasibility, and outcome expectations.

## Revised recommendations (16)

### 2018 Guidelines on myocardial revascularization

Class

#### *Recommendations for revascularization in patients with chronic coronary syndrome*

#### *Revascularization to improve outcomes - In CCS*

In patients with one- or two-vessel disease, PCI should be considered as an alternative to CABG when complete revascularization is achieved.

IIa

#### *Revascularization to improve outcomes - In CCS*

In patients with three-vessel disease, PCI should be considered as an alternative to CABG when the evaluation by the patient's coronary expected complete revascularization, despite comorbidities.

IIa

## Revised recommendations (18)

### 2018 Guidelines on myocardial revascularization

Class

Level

### 2024 Guidelines

Class

Level

#### *Anatomically and clinically based recommendations for revascularization in CCS*

#### *Left main with multivessel disease*

For left main disease with high SYNTAX score ( $\geq 33$ ), PCI.

III

B

In CCS patients at high surgical risk, PCI may be considered over medical therapy alone.

IIb

B

#### *Multivessel disease and diabetes*

For CCS patients with diabetes and three-vessel disease with low SYNTAX score 0–22, PCI.

IIb

A

In CCS patients at very high surgical risk, PCI should be considered over medical therapy alone to reduce symptoms and adverse outcomes.

IIa

B

For CCS patients with diabetes and three-vessel disease with intermediate or high SYNTAX score (>22), PCI.

III

A

2024 ESC Guidelines for the management of chronic coronary syndromes (European Heart Journal; 2024 – doi: 10.1093/euroheart/ehae177)

### 2018 Guidelines on myocardial revascularization

Class

Level

2024 Guidelines

Class

Level

#### *Anatomically and clinically based recommendations for revascularization in CCS*

#### *Left main disease*

Left main disease with low SYNTAX score (0–22), PCI.

Class

Level

I

A

In CCS patients with significant left main coronary stenosis of low complexity (SYNTAX score  $\leq 22$ ), in whom PCI can provide equivalent completeness of revascularization to that of CABG, PCI is recommended as an alternative to CABG, given its lower invasiveness and non-inferior survival.

I

A

Left main disease with intermediate SYNTAX score (23–32), PCI.

IIa

A

In CCS patients with significant left main coronary stenosis of intermediate complexity (SYNTAX score 23–32), in whom PCI can provide equivalent completeness of revascularization to that of CABG, PCI

IIa

A

should be considered, given its lower invasiveness and non-inferior survival.

2024 ESC Guidelines for the management of chronic coronary syndromes (European Heart Journal; 2024 – doi: 10.1093/euroheart/ehae177)

#### *Revascularization to improve outcomes - In CCS*

In CCS patients with significant left main coronary stenosis of intermediate complexity (SYNTAX score 23–32), in whom PCI can provide equivalent completeness of revascularization to that of CABG, PCI

I

C

should be considered, given its lower invasiveness and non-inferior survival.

I

C

In CCS patients with significant left main coronary stenosis of high complexity (SYNTAX score  $\geq 33$ ), PCI

I

C

should be considered, given its lower invasiveness and non-inferior survival.

I

C

## New recommendations (17)



### Recommendations

#### *Mode of revascularization in patients with chronic coronary syndrome*

Class

Level

#### *Left main disease*

In CCS patients at low surgical risk with significant left main coronary stenosis, CABG:

I

A

- is recommended over medical therapy alone to improve survival;

is recommended as the overall preferred revascularization mode over PCI, given the lower risk of spontaneous myocardial infarction and repeat revascularization.

I

A

In CCS patients with significant left main coronary stenosis of low complexity (SYNTAX

I

A

revascularization to that of CABG, given its lower invasiveness and non-inferior survival.

I

A

2024 ESC Guidelines for the management of chronic coronary syndromes (European Heart Journal; 2024 – doi: 10.1093/euroheart/ehae177)

## New recommendations (17)

### Recommendations

#### *Mode of revascularization in patients with chronic coronary syndrome*

#### *Left main disease*

In CCS patients at low surgical risk with significant left main coronary stenosis, CABG:

I

A

- is recommended over medical therapy alone to improve survival;

is recommended as the overall preferred revascularization mode over PCI, given the lower risk of spontaneous myocardial infarction and repeat revascularization.

I

A

In CCS patients with significant left main coronary stenosis of low complexity (SYNTAX

I

A

revascularization to that of CABG, given its lower invasiveness and non-inferior survival.

I

A

In CCS patients with significant left main coronary stenosis of intermediate complexity (SYNTAX score 23–32), PCI:

I

C

- is recommended over medical therapy alone to reduce symptoms and adverse outcomes.

I

C

In CCS patients with significant left main coronary stenosis of high complexity (SYNTAX score  $\geq 33$ ), PCI:

I

C

should be considered, given its lower invasiveness and non-inferior survival.

I

C

In CCS patients with significant left main coronary stenosis of intermediate complexity (SYNTAX score 23–32), PCI:

I

C

should be considered, given its lower invasiveness and non-inferior survival.

I

C

In CCS patients with significant left main coronary stenosis of high complexity (SYNTAX score  $\geq 33$ ), PCI:

I

C

should be considered, given its lower invasiveness and non-inferior survival.

I

C

In CCS patients with significant left main coronary stenosis of intermediate complexity (SYNTAX score 23–32), PCI:

I

C

should be considered, given its lower invasiveness and non-inferior survival.


I

C


2024 ESC Guidelines for the management of chronic coronary syndromes (European Heart Journal; 2024 – doi: 10.1093/euroheart/ehae177)

**Figure 1**

**Central illustration:**  
Clinical presentations  
of CCS and  
mechanisms of  
myocardial ischaemia

**Figure 4**

## Estimation of the clinical likelihood of obstructive CAD



Clinical Likelihood (RF-CL)

	Women	Men
0–1	0–3	0–5
2	4–10	6–12
3	11–17	13–20
4	18–24	21–27
5	25–31	32–39


2024 ESC Guidelines for the management of chronic coronary syndromes (European Heart Journal; 2024 – doi: 10.1093/eurheartj/ehae177)

**Figure 3**


Main CCS symptoms:  
angina and exertional  
dyspnoea

## Adjustment and reclassification of the estimated clinical likelihood of obstructive CAD

Dyspnoea	Quality	+ Difficult to tolerate	+ Difficult catching breath
	Trigger	+ Both at rest and on effort	+ On effort
	Relief	+ Slowly subsiding at rest or after inhalation of bronchodilators	+ Rapidly subsiding after effort discontinuation



2024 ESC Guidelines for the management of chronic coronary syndromes (European Heart Journal; 2024 – doi: 10.1093/eurheartj/ehae177)



2024 ESC Guidelines for the management of chronic coronary syndromes (European Heart Journal; 2024 – doi: 10.1093/eurheartj/ehae177)



Clinical Likelihood (RF-CL)

	Women	Men
0–1	0–3	0–5
2	4–10	6–12
3	11–17	13–20
4	18–24	21–27
5	25–31	32–39

2024 ESC Guidelines for the management of chronic coronary syndromes (European Heart Journal; 2024 – doi: 10.1093/eurheartj/ehae177)



Clinical Likelihood (RF-CL)

	Women	Men
0–1	0–3	0–5
2	4–10	6–12
3	11–17	13–20
4	18–24	21–27
5	25–31	32–39

2024 ESC Guidelines for the management of chronic coronary syndromes (European Heart Journal; 2024 – doi: 10.1093/eurheartj/ehae177)

# La rivascolarizzazione in CCS può

## ► **Migliorare i sintomi**

- ▶ Ridurre angina o equivalente anginosi
- ▶ In caso di Failure della terapia medica ottimale

## ► **Ridurre Ischemia**


- ▶ Va documentata con test adeguati

## ► **Migliorare la prognosi**


- ▶ Quando vi è estensione della coronaropatia in più vasi
- ▶ Coinvolgimento del Tronco comune
- ▶ Scompenso cardiaco

## Proportion of Patients with Ischemic Myocardium as a Function of Ischemia



All Patients



Patients with LVEF <45%



# Revascularization vs Medical Therapy and Extent of Ischemia







# Come calcolare ischemia

- ▶ PET
- ▶ Stress Ecografia
- ▶ RMN con stress
  
- ▶ Tac con stress

59 anni M, agosto 2022 NSTEMI sottoposto  
a PTCA ed impianto di DES su IVA

## Clinical case #1






## Clinical case #1


CTP Acquisizione: dinamica, scanner DSCT

Stress Agent: regadenoson

Mdc ev: visipaque 320 mg/l, @40 cc 5.5.ml/s



69 Myocardial Blood Flow  
MBF / (mL/100mL/min)



## Trattamento del Tronco Comune

- ▶ Pazienti con bassa complessità Syntax <22 possono essere trattati con PCI perché più semplice rispetto al CABG
- ▶ Pazienti con complessità intermedia SYN >23 e <32, dove PCI può essere completa come con CABG si preferisce la PCI.

# Syntax Score

**SYNTAX SCORE II**

Score: 15      Dominance: right      Current lesion: 1/1

For reliable results, please do not use your browser's back button - Calculator version 2.28

**3. Specify which segments are diseased for lesion 1.** i  
Click on the coronary tree image to select or unselect segments.

	Segments:	Lesion:	1
<b>RCA</b>	RCA proximal	1	<input type="checkbox"/>
	RCA mid	2	<input type="checkbox"/>
	RCA distal	3	<input type="checkbox"/>
	Posterior descending	4	<input type="checkbox"/>
	Posteriorolateral from RCA	16	<input type="checkbox"/>
	Posteriorolateral from RCA	16a	<input type="checkbox"/>
	Posteriorolateral from RCA	16b	<input type="checkbox"/>
	Posteriorolateral from RCA	16c	<input type="checkbox"/>
<b>LM</b>	Left main	5	<input type="checkbox"/>
<b>LAD</b>	LAD proximal	6	<input type="checkbox"/>
	LAD mid	7	<input type="checkbox"/>
	LAD apical	8	<input type="checkbox"/>
	First diagonal	9	<input type="checkbox"/>
	Add. first diagonal	9a	<input type="checkbox"/>
	Second diagonal	10	<input type="checkbox"/>
	Add. second diagonal	10a	<input type="checkbox"/>
<b>LCX</b>	Proximal circumflex	11	<input type="checkbox"/>
	Intermediate/anterolateral	12	<input type="checkbox"/>
	Obtuse marginal	12a	<input type="checkbox"/>
	Obtuse marginal	12b	<input type="checkbox"/>
	Distal circumflex	13	<input type="checkbox"/>
	Left posterolateral	14	<input type="checkbox"/>
	Left posterolateral	14a	<input type="checkbox"/>
	Left posterolateral	14b	<input type="checkbox"/>

	Segments:	Lesion:	1
<b>RCA</b>	RCA proximal	1	<input checked="" type="checkbox"/>
	RCA mid	2	<input type="checkbox"/>
	RCA distal	3	<input type="checkbox"/>
	Posterior descending	4	<input type="checkbox"/>
	Posteriorolateral from RCA	16	<input type="checkbox"/>
	Posteriorolateral from RCA	16a	<input type="checkbox"/>
	Posteriorolateral from RCA	16b	<input type="checkbox"/>
	Posteriorolateral from RCA	16c	<input type="checkbox"/>
<b>LM</b>	Left main	5	<input checked="" type="checkbox"/>
<b>LAD</b>	LAD proximal	6	<input type="checkbox"/>
	LAD mid	7	<input checked="" type="checkbox"/>
	LAD apical	8	<input type="checkbox"/>
	First diagonal	9	<input type="checkbox"/>
	Add. first diagonal	9a	<input type="checkbox"/>
	Second diagonal	10	<input type="checkbox"/>
	Add. second diagonal	10a	<input type="checkbox"/>
<b>LCX</b>	Proximal circumflex	11	<input checked="" type="checkbox"/>
	Intermediate/anterolateral	12	<input type="checkbox"/>
	Obtuse marginal	12a	<input type="checkbox"/>
	Obtuse marginal	12b	<input type="checkbox"/>
	Distal circumflex	13	<input type="checkbox"/>
	Left posterolateral	14	<input type="checkbox"/>
	Left posterolateral	14a	<input type="checkbox"/>
	Left posterolateral	14b	<input type="checkbox"/>

[next](#)

[Click here for segment definitions](#)



CARDIALYSIS  
Boston Scientific

# Pazienti MVD con FE ridotta

- ▶ Preferire sempre il CABG sulla terapia medica se FE< 35%
- ▶ PCI possibile solo se è alto il rischio chirurgico ma è sconsigliata se Syn score >33
- ▶ PCI o CABG nei casi MVD devono essere valutati da Heart Team
  - ▶ Se non disponibile on site, HT è consigliato per scegliere il miglior trattamento possibile per il paziente
  - ▶ La comunicazione con il paziente deve essere bilanciata e chiara
  - ▶ La scelta del paziente deve essere presa in massima considerazione

# Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction

STICHES




reduction AMI type I

ESC Congress 2024  
London & Online

N Engl J Med 2016;374:1511-1520

# Revived-BCIS 2



## No. at Risk


PCI	347	295	262	179	130	80	32	14	3
Optimal medical therapy	353	299	276	191	142	82	33	10	1

## Lesion preparation strategies for calcific CAD

### Ablative techniques



Rotational atherectomy



Orbital atherectomy


### Balloon-based techniques



Super high-pressure balloon



Cutting-/Scoring balloon



Intravascular lithotripsy

modification/ablation of the plaque composition (especially the hard-calcified component) to promote stent expansion



cracking of the calcium component to increase plaque elasticity and allow stent expansion

De Maria et al. JACC Int. 2019



Laser Eccimer

# Which intravascular imaging (IVI) for MVD




# The totality of data

- 22 randomized trials
  - *IVUS vs angiography*
  - *OCT vs angiography*
  - *IVUS or OCT vs angiography*
  - *OCT vs IVUS*
  - All using DES
- 15,964 patients
- Mean FU: 24.7 months
- Primary endpoint: TLF

## Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis

Gregg W Stone, Evald H Christiansen, Ziad A Ali, Lene N Andreasen, Akiko Maehara, Yousif Ahmad, Ulf Landmesser, Niels R Holm



The Lancet 2024

# The totality of data

- 22 randomized trials
  - *IVUS vs angiography*
  - *OCT vs angiography*
  - *IVUS or OCT vs angiography*
  - *OCT vs IVUS*
  - All using DES
- 15,964 patients
- Mean FU: 24.7 months
- Primary endpoint: TLF

## IVUS/OCT vs angiography


Reduction by imaging-guided PCI:

- Target Lesion Failure: 29%
- Cardiac death: 45%
- Target vessel MI: 18%
- Ischemia-driven TLR: 28%
- Stent thrombosis: 47%
- Any MI: 16%
- All-cause mortality: 25%

Stone et al The Lancet 2024


Since: IVUS-ACS trial and OCCUPI added to the superiority of IVUS and OCT over angiographic guidance

## Routine OCT vs ad hoc IVUS (16%)



30% RR reduction

The NEW ENGLAND JOURNAL of MEDICINE




MACE: cardiac death, target lesion myocardial infarction, ischemia-driven target lesion revascularization


Kaplan Meier estimates  
Comparison by unadjusted Cox analysis  
Confirmed by adjusted Cox analysis



## Indications that could favor IVUS or OCT




- Culprit detection
- Stent failure
- Complex bifurcations
- Calcified lesions



- Ostial Left Main
- CTO
- Renal failure
- Poor guide support

# OCT or IVUS?



vs.




## IVUS vs Angio

Direct estimate (12 trials, 6856 patients)

Indirect estimate

Network estimate



vs.





## OCT vs Angio


Direct estimate (8 trials, 4726 patients)

Indirect estimate

Network estimate



vs.



## OCT vs IVUS

Direct estimate (5 trials, 3324 patients)

Indirect estimate

Network estimate

Target lesion failure at median 24.7months  
Stone et al. The Lancet 2024

# Calcium Score





Artery	Lesions	Volume / mm³	Equiv. Mass / mg	Score
LM	1	137,1	34,90	162,2
LAD	4	520,5	151,85	643,4
CX	5	174,7	34,89	207,5
RCA	1	36,0	8,18	43,7
Ca	0	0,0	0,00	0,0
Total	11	868,3	229,82	1056,8
U1	0	0,0	0,00	0,0
U2	0	0,0	0,00	0,0



## Settings

Score Type: Agatston equivalent, Threshold: 130 HU (105,3 mg/cm³ CaHA)  
Mass calibration factor: 0,81

Grazie a Serena Dell'Aversana




# CORO TAC ed FFRCT






LCX



0.92



1.0

0.9

0.8



0.7

0.6


0.5

Diameter < 1.8mm



RCA\_2





Branch	Vessel	DVFFR
Left Coronary	LAD	0.62
	LCX	0.92
Right Coronary	RCA	0.84




**Preparazione della placca con Laser e poi Shockwave**  
**Impianto di 2 stent 3.0x33 e 3.5 28**



# Studio della placca



Grazie a Serena Dell'Aversana



RCA

A: 67 %  
D: 42 %



▲ = 9,9 mm


--



--


--











# Conclusioni

Le linee guida CCS 2024 sono centrate sul paziente

Ritagliano un ruolo importante alla rivascolarizzazione percutanea  
Sia come prima scelta ma anche in alternativa al by pass in molti setting clinici  
In accordo condiviso in Heart Team

Le tecniche di Imaging intravascolare devono essere implementate anche per  
Ridurre il gap con la CCH

Le nuove tecniche diagnostiche TAC ( Con stress Farmacologico e con FFR)  
Già da oggi permettono di praticare diagnosi precise e permettono di  
Programmare le tecniche di rivascolarizzazione più adeguate





# Figure 11

## Antithrombotic treatment in CCS patients undergoing PCI

